| Member | Buys | Sells | Est. net | Last move |
|---|---|---|---|---|
| April McClain Delaney MD06 | 11 | 4 | −$111.0K | Sold Aug 25, 26 |
| Rob Bresnahan PA08 | 2 | 1 | +$8.0K | Bought May 15, 25 |
| Gilbert Cisneros CA31 | 1 | −$8.0K | Trimmed Mar 31, 25 |
| Traded | Member | Owner | Type | Amount | Filed | Report |
|---|---|---|---|---|---|---|
| Aug 25, 26 | April McClain Delaney MD06 | Child | Sell | $100,001 - $250,000 | Sep 9, 26 (15d) | |
| Aug 7, 26 | April McClain Delaney MD06 | Child | Sell (part) | $1,001 - $15,000 | Sep 9, 26 (33d) | |
| Aug 6, 26 | April McClain Delaney MD06 | Child | Sell (part) | $1,001 - $15,000 | Sep 9, 26 (34d) | |
| Aug 5, 26 | April McClain Delaney MD06 | Child | Sell (part) | $1,001 - $15,000 | Sep 9, 26 (35d) | |
| Feb 11, 26 | April McClain Delaney MD06 | Child | Buy | $1,001 - $15,000 | Mar 10, 26 (27d) | |
| Feb 4, 26 | April McClain Delaney MD06 | Child | Buy | $1,001 - $15,000 | Mar 10, 26 (34d) | |
| Jan 28, 26 | April McClain Delaney MD06 | Child | Buy | $1,001 - $15,000 | Feb 2, 26 (5d) | |
| Nov 17, 25 | April McClain Delaney MD06 | Child | Buy | $1,001 - $15,000 | Dec 8, 25 (21d) | |
| Oct 31, 25 | April McClain Delaney MD06 | Child | Buy | $1,001 - $15,000 | Nov 4, 25 (4d) | |
| Oct 29, 25 | April McClain Delaney MD06 | Child | Buy | $1,001 - $15,000 | Nov 4, 25 (6d) | |
| May 15, 25 | Rob Bresnahan PA08 | Self | Buy | $1,001 - $15,000 | May 31, 25 (16d) | |
| Apr 8, 25 | Rob Bresnahan PA08 | Self | Sell | $1,001 - $15,000 | May 8, 25 (30d) | |
| Mar 31, 25 | Gilbert Cisneros CA31 | Self | Sell (part) | $1,001 - $15,000 | Apr 7, 25 (7d) | |
| Feb 28, 25 | April McClain Delaney MD06 | Child | Buy | $1,001 - $15,000 | Mar 20, 25 (20d) | |
| Feb 27, 25 | April McClain Delaney MD06 | Child | Buy | $1,001 - $15,000 | Mar 20, 25 (21d) | |
| Feb 25, 25 | Rob Bresnahan PA08 | Self | Buy | $1,001 - $15,000 | Mar 27, 25 (30d) | |
| Feb 17, 25 | April McClain Delaney MD06 | Child | Buy | $1,001 - $15,000 | Mar 20, 25 (31d) | |
| Feb 8, 25 | April McClain Delaney MD06 | Child | Buy | $1,001 - $15,000 | Mar 20, 25 (40d) | |
| Feb 5, 25 | April McClain Delaney MD06 | Child | Buy | $1,001 - $15,000 | Mar 20, 25 (43d) |
From the House's STOCK Act reports (Senate not included). Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Aug 16, 2026 | Anderson Kerrii BDirector | Sale at price 318.02 per share. | 3K | $954.06K |
| Aug 10, 2026 | Schechter Adam HChief Executive Officer | Sale at price 320.37 per share. | 4.7K | $1.50M |
| Aug 3, 2026 | Summy Amy BOfficer | Sale at price 306.74 per share. | 924 | $283.43K |
| Aug 2, 2026 | Wilkinson Peter JOfficer | Sale at price 309.22 - 309.23 per share. | 1.4K | $439.11K |
| Aug 2, 2026 | Wilkinson Peter JOfficer | Conversion of Exercise of derivative security at price 209.25 per share. | 1.3K | $279.98K |
| Jul 1, 2026 | Kyle Kathryn WOfficer | Sale at price 286.19 per share. | 92 | $26.33K |
| Jul 1, 2026 | Vaughn Bryan TOfficer | Sale at price 286.19 per share. | 234 | $66.97K |
| Jun 30, 2026 | Kyle Kathryn WOfficer | — | 256 | — |
| Jun 30, 2026 | Vaughn Bryan TOfficer | — | 327 | — |
| Jun 7, 2026 | Kyle Kathryn WOfficer | Sale at price 263.89 per share. | 762 | $201.08K |
| May 10, 2026 | Schechter Adam HChief Executive Officer | Sale at price 254.50 per share. | 5.9K | $1.50M |
| Mar 26, 2026 | Wilkinson Peter JOfficer | Sale at price 267.05 per share. | 1.6K | $436.09K |
| Mar 26, 2026 | Meltzer Jonathan COfficer | Sale at price 267.05 per share. | 839 | $224.06K |
| Mar 25, 2026 | Vaughn Bryan TOfficer | Stock Award(Grant) at price 0.00 per share. | 1.6K | — |
| Mar 25, 2026 | Van Der Vaart Sandra DillardOfficer | Stock Award(Grant) at price 0.00 per share. | 6.4K | — |
| Mar 25, 2026 | Caveney Brian JOfficer | Stock Award(Grant) at price 0.00 per share. | 11.3K | — |
| Mar 25, 2026 | Schroeder Mark SChief Operating Officer | Stock Award(Grant) at price 0.00 per share. | 12.3K | — |
| Mar 25, 2026 | Summy Amy BOfficer | Stock Award(Grant) at price 0.00 per share. | 4K | — |
| Mar 25, 2026 | Bailey Megan DOfficer | Stock Award(Grant) at price 0.00 per share. | 1.2K | — |
| Mar 25, 2026 | Oyegunwa AkinboladeChief Technology Officer | Stock Award(Grant) at price 0.00 per share. | 1.3K | — |
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 8.2 | 6.5 | -7.7 | -3.8 | 1.3 | 7.7 | 10.4 | 7.6 | -7.4 | 2.4 | +25.8% | ||
| 2025 | 8.9 | 0.5 | -7.3 | 3.6 | 3.3 | 5.4 | -0.9 | 6.9 | 3.3 | -11.5 | 5.8 | -6.7 | +9.4% |
| 2024 | -2.2 | -2.9 | 1.2 | -7.8 | -3.2 | 4.4 | 5.9 | 6.7 | -2.8 | 2.1 | 5.6 | -4.9 | +0.9% |
| 2023 | 7.1 | -5.1 | -4.2 | -1.2 | -6.3 | 13.6 | 3.2 | -2.7 | -3.4 | -0.7 | 8.6 | 4.8 | +12.4% |
| 2022 | -13.6 | -0.0 | -2.8 | -8.9 | 2.7 | -5.0 | 11.9 | -14.1 | -9.1 | 8.3 | 8.5 | -2.2 | −25.1% |
| 2021 | 12.5 | 4.8 | 6.3 | 4.3 | 3.2 | 0.5 | 7.4 | 2.4 | -7.2 | 2.0 | -0.6 | 10.1 | +54.4% |
| 2020 | 3.7 | 0.2 | -28.1 | 30.1 | 6.6 | -5.3 | 16.1 | -8.9 | 7.1 | 6.1 | 0.0 | 1.9 | +20.3% |
| 2019 | 10.3 | 6.4 | 3.2 | 4.5 | 1.7 | 6.3 | -3.1 | 0.0 | 0.3 | -1.9 | 4.6 | -1.8 | +33.9% |
| 2018 | 9.4 | -1.0 | -6.3 | 5.6 | 5.8 | -0.6 | -2.3 | -1.4 | 0.5 | -7.6 | -9.3 | -13.2 | −20.8% |
| 2017 | 4.5 | 6.0 | 0.9 | -2.3 | -0.8 | 10.9 | 3.1 | -1.3 | -3.8 | 1.8 | 3.0 | 0.8 | +24.2% |
| 2016 | -9.1 | -2.2 | 6.6 | 7.0 | 2.1 | 1.8 | 7.1 | -1.9 | 0.4 | -8.8 | 0.4 | 2.0 | +3.8% |
| 2015 | 6.4 | 7.2 | 2.5 | -5.2 | -1.3 | 2.8 | 5.0 | -7.4 | -7.9 | 13.2 | -1.0 | 1.7 | +14.6% |
| 2014 | -1.7 | 4.1 | 5.0 | 0.5 | 3.9 | -0.2 | 1.3 | 3.4 | -5.1 | 7.4 | -4.3 | 3.1 | +18.1% |
| 2013 | 3.3 | -1.0 | 1.8 | 3.5 | 6.6 | 0.6 | -3.4 | -1.1 | 3.6 | 1.8 | 0.9 | -10.3 | +5.5% |
| 2012 | 6.3 | -1.6 | 1.8 | -4.0 | -5.2 | 11.2 | -9.2 | 4.6 | 5.1 | -8.4 | -0.2 | 2.4 | +0.8% |
| 2011 | 2.3 | 0.2 | 2.2 | 4.7 | 4.5 | -4.0 | -6.2 | -8.0 | -5.4 | 6.1 | 2.2 | 0.3 | −2.2% |
| 2010 | -5.0 | 3.1 | 3.3 | 3.8 | -3.8 | -0.3 | -3.1 | -0.5 | 8.0 | 3.7 | 0.9 | 7.2 | +17.5% |
| 2009 | -8.1 | -7.1 | 6.3 | 9.7 | -5.0 | 11.2 | -0.9 | 3.9 | -5.9 | 4.9 | 5.9 | 2.6 | +16.2% |
| 2008 | -2.3 | 4.8 | -4.7 | 2.6 | -2.4 | -5.6 | -2.9 | 8.2 | -5.0 | -11.5 | 3.0 | 1.7 | −14.7% |
| 2007 | -0.0 | 8.5 | -8.8 | 8.7 | -0.3 | -0.6 | -5.6 | 5.2 | 0.7 | -12.1 | 5.7 | 3.9 | +2.8% |
Labcorp Holdings Inc. provides laboratory services. It operates in Diagnostics Laboratories and Biopharma Laboratory Services segments. The company offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, PAP tests, hemoglobin A1C, PSA, tests for sexually transmitted diseases, vitamin D testing, microbiology cultures and procedures, and alcohol and other substance abuse tests. It also provides specialty testing services comprising gene-based and esoteric testing; advanced tests target specific diseases; services related to anatomic pathology/oncology, cardiovascular disease, coagulation, diagnostic genetics, endocrinology, infectious disease, women's health, pharmacogenetics, parentage and donor testing, occupational testing service, medical drug monitoring services, chronic disease programs, and kidney stone prevention tests; and health and wellness services to employers and managed care organizations. In addition, it offers digital pathology solutions, a pathology platforms that support the digitization, centralized review, and sharing of pathology slides; provider and payer digital platforms, an online applications for providers, MCOs, and ACOs; online and mobile applications that enable patients to check offerings, schedule PSC visits, check-in upon PSC arrival, complete documentation, access tests and test results, and manage their accounts; and Generative AI enabled Test Selection, a generative AI enabled tool. It serves clients, third party, medicare/medicaid, patients, pharmaceutical, biotechnology, medical device, diagnostic companies, and CROs. It has a strategic collaboration with the Children's Hospital of Philadelphia to accelerate the discovery, development, and availability of pediatric diagnostics; a strategic alliance with the National Association of Community Health Centers to support current and emerging clinical leaders through the NACHC Leadership Exchange for Chief Medical Officers; and Alliance for Clinical Trials in Oncology to advance national clinical trial for patients diagnosed with colorectal cancer. The company was founded in 1995 and is headquartered in Burlington, North Carolina.
Buy / hold / sell counts